David P. Harrington, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nutrition Therapy | 2 | 2019 | 102 | 1.230 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1676 | 0.800 |
Why?
|
Drug Approval | 3 | 2020 | 815 | 0.650 |
Why?
|
Progestins | 1 | 2020 | 304 | 0.630 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2018 | 26 | 0.620 |
Why?
|
Biometry | 4 | 2008 | 558 | 0.610 |
Why?
|
Renin-Angiotensin System | 1 | 2020 | 738 | 0.510 |
Why?
|
HIV Protease | 2 | 2005 | 97 | 0.490 |
Why?
|
Regional Health Planning | 2 | 2014 | 94 | 0.480 |
Why?
|
Burn Units | 1 | 2014 | 141 | 0.450 |
Why?
|
Antiviral Agents | 3 | 2020 | 3062 | 0.440 |
Why?
|
Angiography | 21 | 1990 | 1608 | 0.380 |
Why?
|
Biological Products | 1 | 2018 | 914 | 0.320 |
Why?
|
Confidentiality | 1 | 2013 | 610 | 0.320 |
Why?
|
Linear Models | 4 | 2010 | 5876 | 0.320 |
Why?
|
Likelihood Functions | 4 | 2002 | 988 | 0.310 |
Why?
|
Premature Birth | 1 | 2020 | 1762 | 0.310 |
Why?
|
Burns | 2 | 2023 | 1864 | 0.310 |
Why?
|
Regression Analysis | 13 | 2010 | 6358 | 0.310 |
Why?
|
Disclosure | 1 | 2013 | 738 | 0.290 |
Why?
|
Quality Assurance, Health Care | 2 | 2014 | 2179 | 0.270 |
Why?
|
Angioplasty, Balloon | 8 | 1995 | 599 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3208 | 0.250 |
Why?
|
Models, Statistical | 9 | 2015 | 5067 | 0.250 |
Why?
|
Repressor Proteins | 1 | 2016 | 2982 | 0.250 |
Why?
|
Neoplasms | 10 | 2019 | 22023 | 0.240 |
Why?
|
Patients | 1 | 2010 | 907 | 0.220 |
Why?
|
Health Surveys | 2 | 2013 | 4059 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2004 | 10329 | 0.220 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15726 | 0.220 |
Why?
|
Research Personnel | 1 | 2008 | 582 | 0.210 |
Why?
|
Patient Satisfaction | 3 | 2012 | 3448 | 0.200 |
Why?
|
Femoral Vein | 2 | 1995 | 153 | 0.200 |
Why?
|
Subtraction Technique | 6 | 1985 | 510 | 0.190 |
Why?
|
Graft Occlusion, Vascular | 6 | 1994 | 555 | 0.190 |
Why?
|
Equipment and Supplies, Hospital | 2 | 1991 | 59 | 0.190 |
Why?
|
Renal Circulation | 5 | 1989 | 292 | 0.190 |
Why?
|
Meta-Analysis as Topic | 2 | 1999 | 1374 | 0.190 |
Why?
|
Colorectal Neoplasms | 5 | 2013 | 6853 | 0.180 |
Why?
|
Asthma | 2 | 2018 | 6159 | 0.180 |
Why?
|
Humans | 151 | 2023 | 759098 | 0.180 |
Why?
|
Clinical Trials as Topic | 10 | 2020 | 8050 | 0.180 |
Why?
|
Femoral Artery | 8 | 1994 | 837 | 0.170 |
Why?
|
Drug Resistance, Viral | 1 | 2005 | 857 | 0.170 |
Why?
|
Liver Abscess, Pyogenic | 1 | 2019 | 7 | 0.170 |
Why?
|
Liver Abscess, Amebic | 1 | 2019 | 20 | 0.170 |
Why?
|
Lung Neoplasms | 9 | 2013 | 13243 | 0.170 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 19 | 2010 | 11656 | 0.170 |
Why?
|
Research Design | 7 | 2019 | 6165 | 0.160 |
Why?
|
Immunization, Passive | 1 | 2020 | 612 | 0.150 |
Why?
|
Esophageal Neoplasms | 4 | 2013 | 1655 | 0.150 |
Why?
|
Taxoids | 4 | 2007 | 668 | 0.150 |
Why?
|
Carbamates | 1 | 2019 | 192 | 0.150 |
Why?
|
Cicatrix | 1 | 2023 | 781 | 0.150 |
Why?
|
Chromosomes, Human, Pair 13 | 3 | 2002 | 194 | 0.140 |
Why?
|
Drugs, Investigational | 1 | 1999 | 214 | 0.140 |
Why?
|
Renal Artery Obstruction | 8 | 1986 | 224 | 0.140 |
Why?
|
Aortography | 2 | 1992 | 420 | 0.140 |
Why?
|
Leg | 6 | 1995 | 1091 | 0.140 |
Why?
|
Deoxycytidine | 4 | 2007 | 860 | 0.140 |
Why?
|
Ethics, Medical | 2 | 1999 | 786 | 0.140 |
Why?
|
Proportional Hazards Models | 5 | 2008 | 12526 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2004 | 859 | 0.130 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 428 | 0.130 |
Why?
|
Quality of Health Care | 2 | 2010 | 4356 | 0.130 |
Why?
|
Trust | 1 | 2020 | 523 | 0.130 |
Why?
|
Vitamin D | 2 | 2019 | 3291 | 0.130 |
Why?
|
Popliteal Vein | 1 | 1995 | 43 | 0.130 |
Why?
|
Survival Analysis | 17 | 2019 | 10181 | 0.130 |
Why?
|
Vascular Patency | 4 | 1995 | 904 | 0.130 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2019 | 475 | 0.130 |
Why?
|
Data Interpretation, Statistical | 4 | 2009 | 2694 | 0.130 |
Why?
|
Fluorouracil | 4 | 2007 | 1621 | 0.120 |
Why?
|
Ovary | 1 | 2019 | 961 | 0.120 |
Why?
|
Maintenance and Engineering, Hospital | 2 | 1991 | 6 | 0.120 |
Why?
|
Colonic Neoplasms | 2 | 1999 | 2519 | 0.120 |
Why?
|
Logistic Models | 5 | 2016 | 13309 | 0.120 |
Why?
|
Ovarian Neoplasms | 3 | 2019 | 4871 | 0.120 |
Why?
|
Treatment Failure | 1 | 2001 | 2641 | 0.120 |
Why?
|
Health Status Disparities | 2 | 2020 | 1818 | 0.120 |
Why?
|
World Health Organization | 1 | 2020 | 1317 | 0.120 |
Why?
|
Stromal Cells | 1 | 2019 | 1326 | 0.120 |
Why?
|
Vasodilator Agents | 3 | 1989 | 976 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 8 | 2001 | 1376 | 0.120 |
Why?
|
Predictive Value of Tests | 4 | 2010 | 15262 | 0.110 |
Why?
|
Aortic Aneurysm | 2 | 1992 | 646 | 0.110 |
Why?
|
Suture Techniques | 1 | 2019 | 789 | 0.110 |
Why?
|
Arterial Occlusive Diseases | 6 | 1990 | 752 | 0.110 |
Why?
|
Blood Vessel Prosthesis | 5 | 1995 | 946 | 0.110 |
Why?
|
Least-Squares Analysis | 1 | 1994 | 369 | 0.110 |
Why?
|
Popliteal Artery | 4 | 1994 | 316 | 0.110 |
Why?
|
Female | 77 | 2020 | 390174 | 0.110 |
Why?
|
Anti-Asthmatic Agents | 1 | 2018 | 563 | 0.110 |
Why?
|
Signal Transduction | 1 | 2016 | 23328 | 0.110 |
Why?
|
Urokinase-Type Plasminogen Activator | 4 | 1990 | 326 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2014 | 4030 | 0.100 |
Why?
|
United States | 11 | 2020 | 72238 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3088 | 0.100 |
Why?
|
Stomach Neoplasms | 3 | 2007 | 1422 | 0.100 |
Why?
|
Catheterization | 6 | 1983 | 1432 | 0.100 |
Why?
|
Paclitaxel | 3 | 2006 | 1716 | 0.100 |
Why?
|
Hepacivirus | 1 | 2019 | 1333 | 0.100 |
Why?
|
Anastomosis, Surgical | 1 | 1995 | 983 | 0.100 |
Why?
|
Ischemia | 7 | 1995 | 1892 | 0.100 |
Why?
|
Filtration | 2 | 1990 | 229 | 0.100 |
Why?
|
Vasomotor System | 2 | 1989 | 207 | 0.100 |
Why?
|
Gene Dosage | 2 | 2006 | 1218 | 0.100 |
Why?
|
Bariatric Surgery | 2 | 2012 | 993 | 0.090 |
Why?
|
Hospital Departments | 2 | 1989 | 136 | 0.090 |
Why?
|
Nuclear Family | 2 | 2006 | 312 | 0.090 |
Why?
|
Organizational Innovation | 1 | 2014 | 535 | 0.090 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 1994 | 290 | 0.090 |
Why?
|
Treatment Outcome | 11 | 2019 | 64867 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2003 | 2499 | 0.090 |
Why?
|
RNA, Viral | 3 | 2019 | 2837 | 0.090 |
Why?
|
Intestine, Small | 1 | 2016 | 1204 | 0.090 |
Why?
|
Mathematical Computing | 1 | 1990 | 143 | 0.090 |
Why?
|
Recurrence | 3 | 2003 | 8465 | 0.090 |
Why?
|
Granulomatous Disease, Chronic | 2 | 2001 | 173 | 0.090 |
Why?
|
Middle Aged | 62 | 2019 | 219628 | 0.080 |
Why?
|
Male | 65 | 2019 | 358602 | 0.080 |
Why?
|
Lung Transplantation | 1 | 2019 | 1299 | 0.080 |
Why?
|
Multiple Myeloma | 6 | 2003 | 5136 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2013 | 11125 | 0.080 |
Why?
|
Prenatal Care | 1 | 2016 | 1125 | 0.080 |
Why?
|
Anti-HIV Agents | 1 | 2005 | 4490 | 0.080 |
Why?
|
Diltiazem | 2 | 1987 | 131 | 0.080 |
Why?
|
Hepatitis C | 1 | 2019 | 1580 | 0.080 |
Why?
|
Program Evaluation | 2 | 2014 | 2487 | 0.080 |
Why?
|
Health Services Research | 3 | 2013 | 1809 | 0.080 |
Why?
|
Disorders of Excessive Somnolence | 1 | 2012 | 277 | 0.080 |
Why?
|
Deglutition Disorders | 1 | 2014 | 629 | 0.080 |
Why?
|
Sleep Apnea, Obstructive | 2 | 2012 | 1861 | 0.080 |
Why?
|
Aged | 47 | 2019 | 168615 | 0.080 |
Why?
|
Disaster Planning | 1 | 2014 | 560 | 0.080 |
Why?
|
Breast Neoplasms | 8 | 2013 | 21019 | 0.080 |
Why?
|
Cesarean Section | 1 | 2016 | 1387 | 0.070 |
Why?
|
Models, Genetic | 3 | 2006 | 3442 | 0.070 |
Why?
|
Chromosome Aberrations | 3 | 2003 | 1772 | 0.070 |
Why?
|
Recovery of Function | 1 | 2018 | 2979 | 0.070 |
Why?
|
Carboplatin | 2 | 2007 | 789 | 0.070 |
Why?
|
HIV-1 | 1 | 2004 | 6848 | 0.070 |
Why?
|
Patient Care Planning | 1 | 2012 | 907 | 0.070 |
Why?
|
Interviews as Topic | 3 | 2013 | 2649 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2010 | 3518 | 0.070 |
Why?
|
Vena Cava, Inferior | 2 | 1988 | 458 | 0.070 |
Why?
|
Data Collection | 3 | 2012 | 3317 | 0.070 |
Why?
|
Reference Standards | 1 | 1990 | 1002 | 0.070 |
Why?
|
Polyglutamic Acid | 1 | 2006 | 44 | 0.070 |
Why?
|
Prognosis | 19 | 2019 | 29559 | 0.070 |
Why?
|
Adult | 51 | 2019 | 219353 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2019 | 2352 | 0.070 |
Why?
|
Radiography, Interventional | 2 | 1993 | 1113 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2019 | 3095 | 0.060 |
Why?
|
Arteriovenous Fistula | 1 | 1988 | 314 | 0.060 |
Why?
|
Genetic Testing | 2 | 1997 | 3531 | 0.060 |
Why?
|
Postoperative Complications | 6 | 2016 | 15662 | 0.060 |
Why?
|
Length of Stay | 2 | 2018 | 6452 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 1995 | 1999 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1343 | 0.060 |
Why?
|
Prednisone | 7 | 2001 | 1563 | 0.060 |
Why?
|
Antineoplastic Agents | 4 | 2006 | 13625 | 0.060 |
Why?
|
Alleles | 2 | 2006 | 6896 | 0.060 |
Why?
|
Models, Biological | 1 | 2001 | 9460 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2016 | 1914 | 0.060 |
Why?
|
Acetylcholine | 2 | 1987 | 629 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 345 | 0.060 |
Why?
|
Computer Simulation | 5 | 2014 | 6195 | 0.060 |
Why?
|
Computers | 5 | 1985 | 595 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 1990 | 1192 | 0.060 |
Why?
|
Cardiomyopathies | 1 | 2016 | 1939 | 0.060 |
Why?
|
Cardiovascular System | 1 | 1992 | 849 | 0.060 |
Why?
|
Radiographic Image Enhancement | 3 | 1987 | 881 | 0.060 |
Why?
|
Tissue Plasminogen Activator | 1 | 1990 | 1188 | 0.060 |
Why?
|
Specialization | 1 | 1989 | 780 | 0.060 |
Why?
|
Lymphoma | 3 | 1988 | 1898 | 0.060 |
Why?
|
Cyclophosphamide | 8 | 2001 | 2218 | 0.060 |
Why?
|
Patient Care Team | 2 | 2016 | 2509 | 0.060 |
Why?
|
Inpatients | 1 | 2015 | 2580 | 0.060 |
Why?
|
Benzazepines | 1 | 1985 | 311 | 0.060 |
Why?
|
Renal Veins | 2 | 1981 | 102 | 0.050 |
Why?
|
Duodenum | 3 | 1983 | 486 | 0.050 |
Why?
|
Pandemics | 2 | 2020 | 8604 | 0.050 |
Why?
|
Clinical Competence | 1 | 2019 | 4775 | 0.050 |
Why?
|
Hypertension, Renovascular | 2 | 1983 | 117 | 0.050 |
Why?
|
Esophagogastric Junction | 1 | 2005 | 343 | 0.050 |
Why?
|
Health Care Surveys | 1 | 2010 | 2434 | 0.050 |
Why?
|
Aneurysm | 2 | 1983 | 337 | 0.050 |
Why?
|
Renin | 3 | 1981 | 637 | 0.050 |
Why?
|
Monitoring, Physiologic | 1 | 1990 | 1783 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2016 | 2938 | 0.050 |
Why?
|
Interferon-gamma | 2 | 2001 | 3123 | 0.050 |
Why?
|
Leukemia, Myeloid | 2 | 1998 | 696 | 0.050 |
Why?
|
DNA, Neoplasm | 3 | 2005 | 1744 | 0.050 |
Why?
|
Pregnancy | 4 | 2020 | 29650 | 0.050 |
Why?
|
Disease-Free Survival | 5 | 2013 | 6814 | 0.050 |
Why?
|
Calcium Channel Blockers | 1 | 1985 | 690 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2009 | 5247 | 0.050 |
Why?
|
Leucovorin | 4 | 1999 | 630 | 0.050 |
Why?
|
Risk Factors | 9 | 2020 | 74167 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2852 | 0.050 |
Why?
|
Transplantation, Autologous | 3 | 2023 | 2119 | 0.050 |
Why?
|
Embolization, Therapeutic | 5 | 1991 | 1412 | 0.050 |
Why?
|
Rhode Island | 2 | 2019 | 350 | 0.050 |
Why?
|
Societies, Medical | 1 | 2014 | 3890 | 0.050 |
Why?
|
Ketanserin | 2 | 1992 | 24 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9372 | 0.050 |
Why?
|
Adenocarcinoma | 3 | 2009 | 6312 | 0.050 |
Why?
|
Fluoxymesterone | 1 | 2001 | 12 | 0.050 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2002 | 286 | 0.050 |
Why?
|
Monosomy | 1 | 2001 | 52 | 0.050 |
Why?
|
HIV Infections | 2 | 2005 | 17126 | 0.050 |
Why?
|
Self Disclosure | 1 | 2002 | 250 | 0.050 |
Why?
|
Birth Rate | 1 | 2002 | 167 | 0.050 |
Why?
|
Gene Amplification | 1 | 2005 | 1085 | 0.050 |
Why?
|
Obesity, Morbid | 1 | 2012 | 1277 | 0.050 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2002 | 410 | 0.050 |
Why?
|
Brachiocephalic Trunk | 1 | 1981 | 41 | 0.050 |
Why?
|
Language | 1 | 2010 | 1525 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2005 | 2058 | 0.050 |
Why?
|
Thrombolytic Therapy | 1 | 1990 | 2106 | 0.050 |
Why?
|
Captopril | 1 | 1981 | 266 | 0.050 |
Why?
|
Pilot Projects | 5 | 2019 | 8530 | 0.050 |
Why?
|
Hypertension, Renal | 1 | 1981 | 139 | 0.050 |
Why?
|
Physician-Patient Relations | 2 | 2012 | 3235 | 0.050 |
Why?
|
Medicine | 1 | 1989 | 943 | 0.040 |
Why?
|
Angiotensin II | 4 | 1989 | 850 | 0.040 |
Why?
|
Cytarabine | 3 | 1998 | 696 | 0.040 |
Why?
|
Renal Artery | 6 | 1987 | 367 | 0.040 |
Why?
|
Mutation | 1 | 2004 | 29878 | 0.040 |
Why?
|
Chromosome Deletion | 2 | 2003 | 1387 | 0.040 |
Why?
|
Spouses | 1 | 2002 | 279 | 0.040 |
Why?
|
Communication | 2 | 2012 | 3846 | 0.040 |
Why?
|
Streptococcus milleri Group | 1 | 2019 | 6 | 0.040 |
Why?
|
Hypertension | 5 | 1989 | 8582 | 0.040 |
Why?
|
Translocation, Genetic | 2 | 2003 | 1388 | 0.040 |
Why?
|
History, 20th Century | 1 | 2008 | 2775 | 0.040 |
Why?
|
Microdissection | 1 | 2019 | 151 | 0.040 |
Why?
|
Arteriosclerosis | 3 | 1992 | 1052 | 0.040 |
Why?
|
Proline | 1 | 1981 | 456 | 0.040 |
Why?
|
Blood Specimen Collection | 1 | 1981 | 238 | 0.040 |
Why?
|
Aged, 80 and over | 17 | 2013 | 58864 | 0.040 |
Why?
|
Preoperative Care | 4 | 2012 | 2256 | 0.040 |
Why?
|
Software | 2 | 2009 | 4421 | 0.040 |
Why?
|
Uncertainty | 1 | 2004 | 754 | 0.040 |
Why?
|
Biliary Tract | 1 | 1980 | 135 | 0.040 |
Why?
|
London | 1 | 2019 | 234 | 0.040 |
Why?
|
HIV Seropositivity | 1 | 2004 | 955 | 0.040 |
Why?
|
Cluster Analysis | 3 | 2015 | 2698 | 0.040 |
Why?
|
Leukemia, Hairy Cell | 2 | 1991 | 83 | 0.040 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 145 | 0.040 |
Why?
|
Developing Countries | 1 | 1991 | 2862 | 0.040 |
Why?
|
Vincristine | 8 | 1998 | 1036 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2013 | 8489 | 0.040 |
Why?
|
Streptococcus | 1 | 2019 | 198 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 260 | 0.040 |
Why?
|
Methotrexate | 4 | 2001 | 1715 | 0.040 |
Why?
|
Antidotes | 1 | 1999 | 139 | 0.040 |
Why?
|
Iliac Artery | 5 | 1986 | 345 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 3960 | 0.040 |
Why?
|
Skin Transplantation | 1 | 2023 | 1036 | 0.040 |
Why?
|
Kidney | 2 | 1985 | 7028 | 0.040 |
Why?
|
Follow-Up Studies | 14 | 2018 | 39213 | 0.040 |
Why?
|
Hematoma | 1 | 1983 | 768 | 0.040 |
Why?
|
Rural Population | 2 | 2013 | 2260 | 0.040 |
Why?
|
Radiography | 14 | 1992 | 6964 | 0.040 |
Why?
|
Bone Marrow Transplantation | 2 | 1998 | 2689 | 0.040 |
Why?
|
Sample Size | 1 | 2001 | 839 | 0.040 |
Why?
|
Markov Chains | 1 | 2001 | 972 | 0.040 |
Why?
|
Mortality | 1 | 1988 | 2913 | 0.040 |
Why?
|
Sequence Deletion | 1 | 2001 | 1494 | 0.030 |
Why?
|
Pancreas | 2 | 1983 | 1674 | 0.030 |
Why?
|
Remission Induction | 8 | 1998 | 2388 | 0.030 |
Why?
|
Registries | 1 | 2013 | 8435 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2006 | 15750 | 0.030 |
Why?
|
Tamoxifen | 1 | 2001 | 962 | 0.030 |
Why?
|
Sodium | 1 | 1981 | 1602 | 0.030 |
Why?
|
Pregnancy, Unplanned | 1 | 2016 | 87 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2013 | 20027 | 0.030 |
Why?
|
Aorta, Abdominal | 2 | 1992 | 623 | 0.030 |
Why?
|
Veins | 3 | 1990 | 765 | 0.030 |
Why?
|
Drug Administration Schedule | 7 | 2010 | 4893 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2001 | 2932 | 0.030 |
Why?
|
Intermittent Claudication | 2 | 1995 | 309 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2005 | 2560 | 0.030 |
Why?
|
Norepinephrine | 2 | 1989 | 899 | 0.030 |
Why?
|
Bleomycin | 6 | 1998 | 496 | 0.030 |
Why?
|
Breast Diseases | 1 | 1978 | 443 | 0.030 |
Why?
|
Cohort Studies | 7 | 2019 | 41266 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2019 | 1003 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6070 | 0.030< |